EULAR

Phase II results suggest drug could outperform existing agents

Vindication for clinicians who ignored official recommendations

Many long-term impacts inevitable, but EULAR attendees mostly optimistic

It isn't good for many

Mainstay drug for RA helpful in disease's earliest stage

Expanding range of conditions caused or aggravated by fine particulates

More than 90% responded at week 12, study showed

Few disease flares and only two serious adverse events thus far in EULAR registry

Risk of death was reduced by 61% in global phase II trial of mavrilimumab

For ANCA-associated vasculitis, fixed retreatment not needed if naive B cells reappear

Benefits seen across all domains in phase IIIb trial

Pivotal phase III trial shows clear efficacy

Similar results to original larger trial seen in post-hoc analysis

Treatment with filgotinib resulted in significant improvements compared with placebo